Coherus Oncology (CHRS) Non-Current Deffered Revenue (2013 - 2017)

Coherus Oncology has disclosed Non-Current Deffered Revenue across 5 years of filings, most recently posting $725000.0 for Q1 2017.

• Non-Current Deffered Revenue for Q1 2017 came in at $725000.0, down 97.8% year-over-year; the trailing twelve-month figure through Mar 2017 was $725000.0 (down 97.8% YoY), and the FY2016 annual result was $669000.0, down 98.52% from the prior year.
• Non-Current Deffered Revenue came in at $725000.0 for Q1 2017 at Coherus Oncology, up from $669000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $45.3 million in Q4 2015 to a low of $595000.0 in Q3 2016.
• The 5-year median for Non-Current Deffered Revenue is $33.2 million (2015), against an average of $27.1 million.
• Across the five-year window, Non-Current Deffered Revenue jumped 39.67% in 2014 and tumbled 98.52% in 2016, its largest moves.
• Coherus Oncology's Non-Current Deffered Revenue stood at $28.6 million in 2013, then soared by 39.67% to $39.9 million in 2014, then grew by 13.63% to $45.3 million in 2015, then sank by 98.52% to $669000.0 in 2016, then grew by 8.37% to $725000.0 in 2017.
• The last three Non-Current Deffered Revenue figures came in at $725000.0 (Q1 2017), $669000.0 (Q4 2016), and $595000.0 (Q3 2016), per Business Quant data.